Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis

Mutation Research - Reviews in Genetic Toxicology

Volumn 366, Issue 1, 1996, Pages 23-44

  Shen, Han Ming ^a   Ong, Choon Nam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Aflatoxin B1; Hepatocellular carcinoma; Mutation; Oxidative DNA damage; p53 tumor suppressor gene; ras oncogene

Indexed keywords

AFLATOXIN B1; PROTEIN P53;

DIET; DNA BINDING; DRUG SPECIFICITY; EXPOSURE; GENETIC ANALYSIS; HUMAN; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MUTATION; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0030272793     PISSN: 01651110     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1110(96)90005-6     Document Type: Article

References (167)

1. 1 induces the transversion of G → T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA. 90:1993;8586-8590.
2. Aguilar F., Harris C.C., Sun T., Hollstein M., Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 264:1994;1317-1319.
3. Ames B.N. Endogenous DNA damage as related to cancer and aging. Mutation Res. 214:1989;41-46.
4. 1 in human lymphocytes. Carcinogenesis. 5:1984;719-723.
5. 1 in woodchucks. Cancer Res. 55:1995;3318-3330.
6. Barbacid M. ras oncogenes: their role in neoplasia. Eur. J. Clin. Invest. 20:1990;225-235.
7. Bauer-Hoffmann R., Buchmann A., Wright A.S., Schwarz M. Mutations in the Ha-ras proto-oncogene in spontaneous and chemically induced liver tumors of the CF1 mouse. Carcinogenesis. 11:1990;1875-1877.
8. 1 with guanines in different DNA sequences. Biochemistry. 27:1988;472-481.
9. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
10. Bourdon J.C., D'Errico A., Paterlini P., Grigioni W., May E., Debuire B. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology. 108:1995;1176-1182.
11. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 350:1991;429-431.
12. Bruce R.D. Risk assessment for aflatoxin: II. Implication of human epidemiology data. Risk Anal. 10:1990;561-569.
13. Buetow K.H., Sheffield V.C., Zhu M., Zhou T., Shen F.M., Hino O., Smith M., McMahon B.J., Lanier A.P., London W.T., et al. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA. 89:1992;9622-9626.
14. Busby W.F., Wogan G.N. Aflatoxins. Searle C.E. Chemical Carcinogens. Vol. 2:1984;945-1136 American Chemical Society, Washington DC.
15. Cai D.W., Gao C.Z., Wang N.J. c-myc gene and p53 protein expression in human primary liver carcinoma (abstract). Chung Hua Ping Li Hsueh Tsa Chih. 23:1994;100-103.
16. 1 in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res. 54:1994;4436-4441.
17. Cerutti P., Hussain P., Pourzand C., Aguilar F. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res. 54:1994;1934s-1938s.
18. Cerutti P.A. Oxy-radicals and cancer. Lancet. 344:1994;862-863.
19. Challen C., Lunec J., Warren W., Collier J., Bassendine M.F. Analysis of the p53 tumor suppressor gene in hepatocellular carcinomas from Britain. Hepatology. 16:1992a;1362-1366.
20. Challen C., Guo K., Collier J.D., Cavanagh D., Bassendine M.F. Infrequent point mutations in codon 12 and 61 of ras oncogenes in human hepatocellular carcinoma. J. Hepatol. 14:1992b;342-346.
21. Chang C., Simmons D.T., Martin M.A., Mora P.T. Identification and partial characterization of new antigents from simian virus 40-transformed mouse cells. J. Virol. 31:1979;371-463.
22. 1. Mol. Carcinogen. 4:1991;112-119.
23. Chen P.H., Lin S.Y., Wang C.K., Chen Y.J., Chen T.C., Chang J.G. 'Hot spots' mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites. Clin. Chem. 39:1993;2186-2191.
24. Chen Y., Tang Z.Y., Li J. Expression of mutant p53 in chronic HBV infection and hepatocellular carcinoma (abstract). Chung Hua Chung Liu Tsa Chih. 16:1994;184-187.
25. Cheng K.C., Cahill D.S., Kasai H., Nishimura S., Loeb L.A. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G to T and A to C substitutions. J. Biol. Chem. 267:1992;166-172.
26. Choi S.W., Hytiroglou P., Geller S.A., Kim S.M., Chung K.W., Park D.H., Theise N.D., Thung S.N. The expression of p53 antigen in primary malignant epithelial tumors of the liver: an immunohistochemical study. Liver. 13:1993;172-176.
27. Collier J.D., Carpenter M., Burt A.D., Bassendine M.F. Expression of mutant p53 protein in hepatocellular carcinoma. Gut. 35:1994;98-100.
28. Coursaget P., Depril N., Chabaud M., Nandi R., Mayelo V., LeCann P., Yvonnet B. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br. J. Cancer. 67:1993;1395-1397.
29. 1 in human cells: effects of sequence context on the supF mutational spectrum. Mutation Res. 306:1994;143-151.
30. 1. Cancer Res. 41:1981;197-203.
31. 1-DNA adduct formed in vivo in rat liver. Proc. Natl. Acad. Sci. USA. 75:1978;1745-1749.
32. D'Errico A., Grigioni W.F., Fiorentino M., Baccarini P., Grazi G.L., Mancini A.M. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol. Int. 44:1994;682-687.
33. De-Benedetti V.M., Welsh J.A., Trivers G.E., Harpster A., Parkinson A.J., Lanier A.P., McMahon B.J., Bennett W.P. p53 is not mutated in hepatocellular carcinomas from Alaska Natives. Cancer Epidemiol. Biomarkers Prev. 4:1995;79-82.
34. Debuire B., Paterlini P., Pontisso P., Basso G., May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene. 8:1993;2303-2306.
35. DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., Old L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA. 76:1979;2420-2424.
36. Diamantis I.D., McGandy C., Chen T.J., Liaw Y.F., Gudat F., Bianchi L. A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma. J. Hepatol. 20:1994;553-556.
37. Duflot A., Hollstein M., Mehrotra R., Trepo C., Montesano R., Cova L. Absence of p53 mutation at codon 249 in duck hepatocellular carcinomas from the high incidence area of Qidong (China). Carcinogenesis. 15:1994;1353-1357.
38. Eaton D.L., Gallagher E.P. Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34:1994;135-172.
39. Ebert R., Barrett J.C., Wiseman R.W., Pechan R., Reiss E., Rollich G., Schiffmann D. Activation of cellular oncogenes by chemical carcinogens in Syrian hamster embryo fibroblasts. Environ. Health Perspect. 88:1990;175-178.
40. 1 in vitro. Proc. Natl. Acad. Sci. USA. 74:1977;1870-1874.
41. Floyd R.A. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis. 11:1990;1447-1450.
42. 1. Proc. Natl. Acad. Sci. USA. 80:1983;2695-2698.
43. Frenkel K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol. Ther. 53:1992;127-166.
44. Fujimoto Y. Aberrations of tumor suppressor genes in hepatocellular carcinomas (abstract). Hokkaido. lgaku. Zasshi. 69:1994;252-260.
45. 1 in nonhuman primates. Cancer Res. 52:1992;1044-1046.
46. Fujimoto Y., Hampton L.L., Wirth P.J., Wang N.J., Xie J.P., Thorgeirsson S.S. Alterations of tumor suppressor gene and allelic losses in human hepatocellular carcinomas in China. Cancer Res. 54:1994;281-285.
47. Fukuda K., Ogasawara S., Maruiwa M., Yano H., Murakami T., Kojiro M. Structural alterations in c-myc and c-Ha-ras proto-oncogenes in human hepatocellular carcinoma (abstract). Kurume Med. J. 35:1988;77-87.
48. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
49. Ghebranious N., Knoll B.J., Wu H., Lozano G., Sell S. Characterization of a murine p53ser249 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol. Carcinogen. 13:1995;104-111.
50. Goldblum J.R., Bartos R.E., Carr K.A., Frank T.S. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am. J. Surg. Pathol. 17:1993;1244-1251.
51. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
52. Groopman J.D., Wogan G.N., Roebuck B.D., Kensler T.W. Molecular biomarkers for aflatoxin and their application to human cancer prevention. Cancer Res. 54:1994;1907s-1911s.
53. Groopman J.D., Cain L.G., Kensler T. Aflatoxin exposure in human populations: measurements and relationship to cancer. CRC Crit. Rev. Toxicol. 19:1988;113-143.
54. Gu J.R., Hu L.F., Cheng Y.C., Wan D.F. Oncogenes in human primary hepatic cancer. J. Cell. Physiol. Suppl. 4:1986;13-20.
55. Hall A.J., Wild C.P. Epidemiology of aflatoxin-related disease. Eaton D.L., Groopman J.D. The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance. 1994;233-258 Academic Press, New York.
56. Harris C.C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res. 51:1991;5023s-5044s.
57. Harris C.C. p53 : At the crossroads of molecular carcinogenesis and risk assessment. Science. 262:1993;1980-1981.
58. Harris C.C., Hollstein M. Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med. 329:1993;1318-1327.
59. Hayashi H., Sugio K., Matsumata T., Adachi E., Tanaka K., Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology. 22:1995;1702-1707.
60. Hayashi H., Sugio K., Matsumata T., Adachi E., Urata K., Tanaka S., Sugimachi K. The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. Liver. 13:1993;279-281.
61. Hayward N.K., Walker G.J., Graham W., Cooksley E. Hepatocellular carcinoma mutation. Nature. 352:1991;764.
62. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
63. 1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer. 53:1993;51-55.
64. Hosono S., Lee C.S., Chou M.J., Yang C.S., Shih C. Molecular analysis of the p53 alleles in primary hepatocellular carcinoma and cell lines. Oncogene. 6:1991;237-248.
65. Hosono S., Chou M.J., Lee C.S., Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene. 8:1993;491-496.
66. Hsia C.C., Kleiner D.E., Axiotis C.A., DiBisceglie A., Nomura A.M., Stemmermann G.N., Tabor E. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J. Natl. Cancer Inst. 84:1992;1638-1641.
67. Hsieh D.P., Atkinson D.N. Recent aflatoxin exposure and mutation at codon 249 of the human p53 gene: lack of association. Food Addit. Contam. 12:1995;421-424.
68. Hsu H.C., Tseng H.J., Lai P.L., Lee P.H., Peng S.Y. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 53:1993a;4691-4694.
69. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
70. Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis. 14:1993b;987-992.
71. 1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res. 53:1993;9-11.
72. Hussain S.P., Aguilar F., Amstad P., Cerutti P. Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene. Oncogene. 9:1994;2277-2281.
73. Imazeki F., Yokosuka O., Ohto M., Omata M. Aflatoxin and p53 abnormality in duck hepatocellular carcinoma. J. Gastroenterol. Hapatol. 10:1995;646-649.
74. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Some naturally occurring substances: Food items and constituents, hetercyclic aromatic amines and mycotoxins. Vol. 56:1993;41-524 IARC, Lyon, France.
75. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Hepatitis viruses. Vol. 59:1994;45-255 IARC, Lyon, France.
76. 1-2,3-oxide. Mutation Res. 179:1987;89-101.
77. Kamiya H., Miura K., Ishikawa H., Inoue H., Nishimura S., Ohtsuka E. C-Ha-ras containing 8-hydroxyguanine at codon 12 induces point mutations at the modified and adjacent positions. Cancer Res. 52:1992;3483-3485.
78. Kamiya H., Murata, Kamiya N., Koizume S., Inoue H., Nishimura S., Ohtsuka E. 8-Hydroxyguanine(7,8-dihydro-8-oxoguanine) in hot spots of the c-Ha-ras gene: effects of sequence contexts on mutation spectra. Carcinogenesis. 16:1995;883-889.
79. Kar S., Jaffe R., Carr B.I. Mutation at codon 249 of p53 gene in a human hepatoblastoma. Hepatology. 18:1993;566-569.
80. Koch W.H., Henrikson E.N., Kupchella E., Cebula T.A. Salmonella typhimurium strain TA100 differentiates several classes of carcinogens and mutagens by base substitution specificity. Carcinogenesis. 15:1994;79-88.
81. 1. Free Radical Res. Commun. 10:1990;137-142.
82. Konishi M., Yanoshita R. Kikuchi, Tanaka K., Sato C., Tsuruta K., Maeda Y., Koike M., Tanaka S., Nakamura Y., Hattori N. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn. J. Cancer Res. 84:1993;893-899.
83. Kress M., May E., Cassingena R., May P. Simian vireus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J. Virol. 31:1979;472-483.
84. Kress S., Jahn U.R., Buchmann A., Bannasch P., Schwarz M. p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res. 52:1992;3220-3223.
85. Kuchino Y., Mori F., Kasai H., Inoue H., Iwai S., Miura K., Ohtsuka E., Nishimura S. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature. 327:1987;77-79.
86. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
87. Laurent-Puig P., Flejou J.F., Fabre M., Bedossa P., Belghiti J., Gayral F., Franco D. Overexpression of p53 : a rare event in a large series of white patients with hepatocellular carcinoma. Hepatology. 16:1992;1171-1175.
88. Lehman T.A., Harris C.C. Mutational spectra of protooncogenes and tumor suppressor genes: clues in predicting cancer etiology. Hemminki K., et al. DNA Adducts: identification and biological significance. IARC Scientific Publications No. 125. 1994;139-412 International Agency for Research on Cancer, Lyon.
89. Leon M., Kew M.C. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res. 15:1995;859-861.
90. Levin A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
91. 1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res. 52:1992;5668-5673.
92. Li D., Cao Y., He L., Wang N.J., Gu J.R. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 14:1993;169-173.
93. 1. Prog. Clin. Biol. Res. 376:1992a;203-222.
94. 1. Mol. Carcinogen. 159:1992b;72-77.
95. 1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res. 37:1977;4430-4438.
96. Linzer I.H., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
97. Livni N., Eid A., Ilan Y., Rivkind A., Rosenmann E., Blendis L.M., Shouval D., Galun E. p53 Expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer. 75:1995;2420-2426.
98. Lowy R.L., Willumsen B.M. Function and regulation of ras. Annu. Rev. Biochem. 62:1993;851-891.
99. 1 with purified DNA. J. Biol. Chem. 262:1987;7455-7462.
100. 1 carcinogenicity. Proc. Soc. Exp. Biol. Med. 208:1995;213-227.
101. McMahon G., Davis E., Wogan G.N. Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. Proc. Natl. Acad. Sci. USA. 84:1987;4974-4978.
102. 1-induced rat liver tumorous. Proc. Natl. Acad. Sci. USA. 87:1990;1104-1108.
103. 1. Proc. Natl. Acad. Sci. USA. 83:1986;9418-9422.
104. Misra R.P., Muench K.F., Humayun M.Z. Covalent and noncovalent interaction of aflatoxin with defined deoxyribonucleic acid sequences. Biochemistry. 22:1983;3351-3359.
105. Moriya M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted GC → TA transversions in simian kidney cells. Proc. Natl. Acad. Sci. USA. 90:1993;1122-1126.
106. Moriya M., Ou C., Bodepudi V., Johnson F., Takeshita M., Grollma A.P. Site-specific mutagenesis using a gapped duplex vector: a study of translation synthesis past 8-oxodeoxyguanosine in E. coli. Mutation Res. 254:1991;281-288.
107. 1-DNA interactions. Proc. Natl. Acad. Sci. USA. 80:1983;6-10.
108. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.
109. Nagao T., Kondo F., Sato T., Nagato Y., Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB 1 immunostaining. Hum. Pathol. 26:1995;326-333.
110. Ng I.O., Srivastava G., Chung L.P., Tsang S.W., Ng M.M. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer. 74:1994a;30-37.
111. Ng I.O., Chung L.P., Tsang S.W., Lam C.L., Lai E.C., Fan S.T., Ng M. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene. 9:1994b;985-990.
112. Nishida N., Fukuda Y., Kokuryu H., Toguchida J., Yandell D.W., Ikenega M. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res. 53:1993;368-372.
113. Nose H., Imazeki F., Ohto M., Omata M. p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer. 72:1993;355-360.
114. Oda T., Tsuda H., Scarpa A., Sakamoto M., Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52:1992;6358-6364.
115. Ogata N., Kamimura T., Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology. 13:1991;31-37.
116. Ojanguren I., Ariza A., Castella E.M., Vasalo A. Fernandez, Mate J.L., Palacios J.J. Navas. p53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology. 26:1995;63-68.
117. Ozturk M. p53 mutations in nonmalignant human liver: fingerprints of aflatoxins? Hepatology. 21:1995;600-601.
118. Ozturk M., et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 338:1991;1356-1359.
119. Patel P., Stephenson J., Scheuer P.J., Francis G.E. p53 Codon -249 (ser) mutations in hepatocellular carcinoma patients with low aflatoxin exposure. Lancet. 339:1992;881.
120. Puisieux A., Lim S., Groopman J., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51:1991;6185-6189.
121. Rivkina M.B., Cullen J.M., Robinson W.S., Marion P.L. State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res. 54:1994;5430-5437.
122. Robinson W.S. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu. Rev. Med. 45:1994;297-323.
123. Ross R., Yuan J.M., Yu M., Wogan G.N., Qian G.S., Tu J.T., Groopman J.D., Gao Y.T., Henderson B.E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 339:1992;943-946.
124. Saegusa M., Takano Y., Kishimoto H., Wakabayashi G., Nohga K., Okudaira M. Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas an enhanced immunohistochemical approach. J. Cancer Res. Clin. Oncol. 119:1993;737-744.
125. 7 adducts as a mutagenic mechanism. Genetics. 129:1991;981-989.
126. 7 position. Genetics. 120:1988;863-873.
127. Schaff Z., Sarosi I., Hsia C.C., Kiss A., Tabor E. p53 in malignant and benign liver lesions. Eur. J. Cancer. 31A:1995;1847-1850.
128. Scorsone K.A., Zhou Y.Z., Butel J.S., Slagle B.L. p53 Mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinoma from China. Cancer Res. 52:1992;1635-1638.
129. Shank R.C., Gordon J.E., Wogan G.N., Nondasuta A., Subhamani B. Dietary aflatoxins and human liver cancer. III. Field survey of rural Thai families for ingested aflatoxins. Food Cosmet. Toxicol. 10:1972;71-84.
130. 1 induced-lipid peroxidation in rat liver. Toxicol. Appl. Pharmacol. 127:1994;145-150.
131. 1-induced 8-hydrodeoxyguanosine formation in rat hepatic DNA. Carcinogenesis. 16:1995;419-422.
132. 1. Free Radic. Biol. Med. 1996;. (in press).
133. Sheu J.C., Huang G.T., Lee P.H., Chung J.C., Chou H.C., Lai M.Y., Wang J.T., Lee H.S., Shih L.N., Yang P.M. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res. 52:1992;6098-6100.
134. Shi C.Y., Phang T.W., Lin Y., Wee A., Li B., Lee H.P., Ong C.N. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Br. J. Cancer. 72:1995;146-149.
135. Shibutani S., Takeshita M., Grollman A.P. Insertion of specific bases during DNA synthesis past the oxidation damaged base 8-oxodG. Nature. 349:1991;431-434.
136. Shieh Y.S., Nguyen C., Vocal M.V., Chu H.W. Tumor suppressor p53 gene in hepatitis C and B virus associated human hepatocellular carcinoma. Int. J. Cancer. 54:1993;558-562.
137. Sinha S., Weber C., Marshall C.J., Knowles M.A., Proctor A. Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis. Proc. Natl. Acad. Sci. USA. 85:1988;3673-3677.
138. Slagle B.L., Zhou Y.Z., Butel J.S. Hepatitis B virus integration event in human chromosome 17q near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res. 51:1991;49-54.
139. 1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient get electrophoresis. Proc. Natl. Acad. Sci. USA. 90:1993;2045-2049.
140. Soussi T., de Fromentel C. Carton, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 5:1990;945-952.
141. Stork P., Loda M., Bosari S., Wiley B., Poppenhusen K., Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene. 6:1991;857-862.
142. Sun T.T., Chu Y.Y. Carcinogenesis and prevention strategy of liver cancer in areas in prevalence. J. Cell. Physiol. 3:(Suppl.):1984;38-44.
143. Tada M., Omata M., Ohto M. Analysis of ras gene mutations in human hepatocellular malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res. 50:1990;1121-1124.
144. Tanaka S., Toh Y., Adachi E., Matsumata T., Mori R., Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res. 53:1993;2884-2887.
145. 1-induced hepatocellular carcinomas. Biochem. Biophys. Res. Commun. 138:1986;858-864.
146. Teramoto T., Satonaka K., Kitazawa S., Fujimori T., Hayashi K., Maeda S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res. 54:1994;231-235.
147. Tiniakos D., Spandidos D.A., Kakkanas A., Pintzas A., Pollice L., Tiniakos G. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res. 9:1989;715-722.
148. Tokusashi Y., Fukuda I., Ogawa K. Absence of p53 mutations and various frequencies of Ki-ras exon 1 mutations in rat hepatic tumors induced by different carcinogens. Mol. Carcinogen. 10:1994;45-51.
149. 1 in a shuttle vector replicating in human cells transiently expressing cytochrome-P450 1A2 cDNA. Mol. Carcinogen. 6:1992;147-148.
150. 1 in serum samples of male Japanese subjects by radioimmumoassay as high-performance liquid chromatography. Cancer Res. 44:1984;1231-1234.
151. Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn. J. Cancer Res. 80:1989;196-199.
152. Unsal H., Yakicier C., Marcais C., Kew M., Volkmann M., Zentgraf H., Isselbacher K.J., Ozturk M. Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;822-826.
153. Van Rensburg S.J., Cook-Mozaffari P., Van Schlkwyk D.J., Van Der Watt J.J., Vinvent T.J., Purchase I.F. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer. 51:1985;713-726.
154. Vesey D.A., Hayward N.K., Cooksley W.G. p53 gene in hepatocellular carcinomas from Australia. Cancer Detect. Prev. 18:1994;123-130.
155. Volkmann M., Hofmann W.J., Muller M., Rath U., Otto G., Zentgraf H., Galle P.R. p53 Overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene. 9:1994;195-204.
156. Wee A., Teh M., Raju G.C. p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. J. Clin. Pathol. 48:1995;236-238.
157. Wild C.P., Jiang Y.Z., Sabbioni G., Chpot B., Montesano R. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res. 50:1990;245-251.
158. Wogan G.N. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res. 52:1992;2114s-2118s.
159. Wood M.L., Dizdaroglu M., Gajewski E., Essigmann J.M. Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroguanine(7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. Biochemistry. 29:1990;7024-7032.
160. Yap E.P., Cooper K., Maharaj B., McGee J.O. p53 codon 249ser hot-spot mutation in HBV-negative hepatocellular carcinoma. Lancet. 341:1993;251.
161. Yeh F.S., Yu M., Mo C.C., Luo S., Tong M.J., Henderson B.E. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi. China. Cancer Res. 49:1989;2506-2509.
162. 1-dichloride to cytosine in DNA. Carcinogenesis. 12:1991;997-1002.
163. Yumoto Y., Hanafusa T., Hada H., Morita T., Ooguchi S., Shinji N., Mitani T., Hamaya K., Koide N., Tsuji T. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 10:1995;179-185.
164. Zhou Y.Z., Slagle B.L., Donehower L.A., van Tuinen P., Ledbetter D.H., Butel J.S. Structural analysis of a hepatitis B virus genome integrated into chromosome 17q of a human hepatocellular carcinoma. J. Virol. 62:1988;4224-4231.
165. Zhu M.H. Hepatitis B X antigen binding to p53 protein in the pathogenesis of primary hepatocellular carcinoma (abstract). Chung Hua I Hsueh Tsa Chih. 73:1993a;325-328.
166. Zhu M.H. Relationship between mutation of tumor suppressor gene p53 and development of hepatocellular carcinoma (abstract). Chung Hua Chung Liu Tsa Chih. 15:1993b;245-247.
167. Zou H.Q., Tang Z.Y., Ye S.L. Mutation of p53 gene and expression of alpha-fetoprotein during hepatocarcinogenesis (abstract). Chung Hua I Hsueh Tsa Chih. 74:1994;474-475.